Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

6.000 +0.010 (+0.17%)
Streaming Delayed Price Updated: 3:25 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 518,862
Open 6.140
Bid (Size) 5.990 (14)
Ask (Size) 6.010 (2)
Prev. Close 5.990
Today's Range 5.990 - 6.380
52wk Range 4.410 - 25.40
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, A LEADING LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-62.51%
-62.51%
1 Month
+21.21%
+21.21%
3 Month
-55.78%
-55.78%
6 Month
-46.64%
-46.64%
1 Year
-75.00%
-75.00%

More News

Read More
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Via Benzinga
Exposures Product Safety
Agenus Inc. Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the AGEN Class Action Lawsuit
From Robbins LLP
Via Business Wire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
From The Rosen Law Firm PA
Via GlobeNewswire
AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
From Agenus Inc.
Via Business Wire
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.
From Robbins LLP
Via GlobeNewswire
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
From Agenus Inc.
Via Business Wire
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Agenus Reports Second Quarter 2024 Operational and Financial Results
From Agenus Inc.
Via Business Wire
Agenus Announces Appointment of Tom Harrison to Board of Directors
From Agenus Inc.
Via Business Wire
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
From Agenus Inc.
Via Business Wire
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Via Benzinga
Exposures Product Safety
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.